Showing results (41-50 of 331) with videos related to
Sort By:
Pageof 34
Expert Review of Clinical Pharmacology|November 21, 2024
Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicityJoy Justice, Roma A Kankaria, Douglas B JohnsonBreast Cancer Research and Treatment|March 11, 2025
Body composition as a potential biomarker of recurrence risk in patients with triple-negative breast cancerJill B De Vis, Cong Wang, Kirsten V Nguyen, et al.Frontiers in Immunology|December 6, 2021
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor TherapySelina K Wong, Caroline A Nebhan, Douglas B JohnsonExpert Opinion on Drug Safety|March 4, 2020
Neurologic complications of immune checkpoint inhibitorsAlexandra M Haugh, John C Probasco, Douglas B JohnsonBMJ Case Reports|June 22, 2025
New-onset dermatomyositis in a patient on nivolumab for metastatic melanomaNina B Curkovic, Douglas B Johnson, Eva Rawlings ParkerOncotarget|November 20, 2020
MEK inhibitors in non-V600 BRAF mutations and fusionsDouglas B Johnson, Caroline A Nebhan, Marcus S NoelClinical Imaging|January 25, 2024
Radiology in the immune checkpoint inhibitor eraBenjamin C Park, Douglas B Johnson, Robert J LewandowskiExpert Review of Clinical Immunology|July 19, 2016
PD-1/PD-L1 blockade in renal cell cancerKathryn E Beckermann, Douglas B Johnson, Jeffrey A SosmanExpert Review of Anticancer Therapy|May 17, 2023
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicityCatherine C Fahey, Thomas J Gracie, Douglas B JohnsonJournal of Bone Oncology|October 16, 2023
Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanismsGwenyth J Joseph, Douglas B Johnson, Rachelle W JohnsonPageof 34